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Background: Hypersensitivity reactions to parenterally administered antibiotics (HRPA) are a substantial problem in managing CF. We conducted
this observational study to assess their nature and frequency as well as risk factors.
Methods: By reviewing medical records and conducting interviews, age, sex, FEV1, ΔF508-genotype, pseudomonal colonisation, allergy history,
antibiotic exposure and HRPA were recorded.
Results: Of 100 patients included in the study, 60 had ≥1 HRPA. Overall, 3205 antibiotic courses with 185 HRPA were ascertained. Changes in
therapy followed 65% of HRPA. Eighty-four percent of severe HRPA occurred during days 1–4. Approximately 10% of treatment courses with
cefepime and piperacillin/tazobactam caused HRPA. Years of pseudomonal colonisation and cumulative annual exposure were signiﬁcant risk factors.
Conclusions: During days 1–4 of antibiotic treatment patients are at elevated risk for HRPA. HRPA are drug-speciﬁc and dependent on cumulative
annual exposure. Elucidation of HRPA's immunological mechanisms and development of diagnostic algorithms for clinical use are required.
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Colistin; Drug Allergy1. Introduction
Due to chronic pulmonary infections patients with cystic
fibrosis (CF) frequently have a very high exposure to intravenous
antibiotics, most commonly, penicillins, cephalosporines and
aminoglycosides. Clinical observations and several cohort
studies [1–4] have demonstrated that hypersensitivity reactions
to parenterally administered antibiotics (HRPA) are a substantial
problem in the management of CF, particularly in patients with☆ Notation of prior abstract publication/presentation: A poster with preliminary
results was presented at the German Cystic Fibrosis Conference 11/2011 in
Wuerzburg/Germany — not published. A poster was presented at the North
American Cystic Fibrosis Conference 10/2012 in Orlando/USA and the abstrac
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⁎ Corresponding author.
E-mail address: jobst.roehmel@charite.de (J.F. Roehmel).
1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Pub
http://dx.doi.org/10.1016/j.jcf.2013.10.002t
rlishedadvanced lung disease. Clinicians are frequently confronted with
HRPA in their day-to-day clinical practice [2,5]. Most common
symptoms are pruritus and rash [1–4]. Since the underlying
mechanisms remain mostly unclear, antibiotic treatment is
frequently terminated, resulting in inconsistent anti-infectious
treatment.
Due to a substantial increase in the life-expectancy for patients
with CF in the last decades [6] and therefore longer treatment
periods, most of the published data about HRPA [1,3,4] do not
reflect today's patients and treatment regimens. Here we present
data of our recent observational study which assessed the nature
and frequency of HRPA as well as predisposing risk factors.2. Methods
2.1. Setting and study population
Of 285 patients with CF (185 adults, 100 children) currently
treated in our center, 100 of 125 pediatric and adult patients,by Elsevier B.V. All rights reserved.
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intravenous antibiotic treatment courses, consented.We restricted
our observations to parenterally administrated antibiotics because
this route of administration is most commonly associated with
hypersensitivity reactions [1]. In contrast to prior publications
[2–4] which focused on β-lactam antibiotics only, we also
included other classes of intravenous (iv) antibiotics. This study
was approved by the ethics committee of Charité — University
Medicine Berlin.
2.2. Study design
After providing written informed consent, patients were
interviewed with a self-designed, semi-open structured
questionnaire asking for treatment centers, FEV1 predicted
(FEV1), CFTR-status, age when diagnosed CF, history of allergy
and atopy, and history of iv antibiotics and HRPA. Then medical
records were reviewed to gather and verify information about:
HRPA, age, sex, latest FEV1, ΔF508 genotype, allergy history
including the latest results of a standard IgE screening test for
aeroallergens (an identical assay was used), specific IgE against
aspergillus, past allergic bronchopulmonary aspergillosis (ABPA),
latest total IgE serum level and years of chronic Pseudomonas
aeruginosa (PA)-colonisation (defined as ≥2 detections/a).
To distinguish patients according to the completeness of
documentation in their medical records, we created three groups:
(i) the total cohort termed “total” comprised of 100 patients
who were currently under treatment at our center, who met the
inclusion criteria and had participated in a face-to-face interview;
(ii) out of those we defined the group “5-year-doc” (N = 66) that
was comprised of patients who had at least 5 years of continuous
medical records at our institution; (iii) out of this latter group
we formed the group “lifetime-doc” (N = 50) that was comprised
of patients whose lifetime medical documentation was available
and done at our centre. For the groups “5-year-doc” and “lifetime-
doc,” we documented every available parenteral antibiotic
treatment course, including the type of antibiotic drug, the length
of treatment course, daily dose and the use of pre-emptive
measures such as rapid desensitisation [5,7] or administration of
anthistamines or corticosteroids.
We defined HRPA as any form of hypersensitivity reaction
occurring during an iv antibiotic treatment course which required
a subsequent medical intervention, such as discontinuation or
change of antibiotic treatment or administration of antihistamines
and corticosteroids. It was further required that previous CF
treatment remained unchanged. No preselection of symptoms in
the sense of allergy symptoms was done. Whenever we could not
identifiy the HRPA-causing antibiotic due to multiple antibiotic
treatment the reaction was excluded from the observations.
Criteria for an antibiotic to be accountable were the onset of the
reaction in relation to the infusion and tolerance to the second
agent after discontinuation of the first (in 69% tobramycine was
one of the two agents).
HRPA were documented in detail including the date of
onset and the day of the antibiotic treatment course, the onset
of the reaction in relation to administration of the infusion,
type of symptoms, treatment of the reaction and continuation(with antiallergic medication), and change or discontinuation
of antibiotic treatment. As the risk of hypersensitivity to an
antibiotic we regarded the proportion of the recorded antibiotic
courses of a given drug which featured an HRPA.
Home iv antibiotic treatments were included whenever
sufficient documentation was available. Reactions involving
the bronchopulmonary (e.g. acute bronchospasm) or the
cardiovascular (e.g. hypotension) system were classified as
severe, reactions meeting the WAO criteria for anaphylaxis
[8] as anphylactic. With regard to their onset, reactions were
classified according to the “European Network of Drug Allergy”
[9]: those during or within 1 hour of the infusion were classified
as “immediate,” all others as “non-immediate.” Following
Hjortlund et al. [10,11] we also classified reactions as immediate
which occurred within treatment courses (days 1–14).
2.3. Statistical analysis
Descriptive analyses in the three (nested) patient populations
were conducted based on the extent of data available for each
group. Student's t-tests for continuously distributed variables
and χ2 tests for proportions were calculated with corresponding
95% confidence intervals and p-values.
Univariate analyses were performed to identify risk factors
for HRPA. For studying the influence of multiple risk factors
on the occurrence of HRPA, a logistic regression model was
developed in the “lifetime-doc” cohort with HRPA as the outcome
variable and age, gender, years of parenteral antibiotic treatment,
FEV1, and years of PA-colonisation as independent variables.
Another logistic regression model analysed these risk factors for
severe reactions only.
Cumulative exposure (gram/year) and lifetime dose to the
twomost HRPA-causing antibiotics were analysed in the “lifetime-
doc” group comparing the subgroups with and without reactions.
Due to obvious deviation from the normal distribution, we utilized
the nonparametric Mann–Whitney–Wilcoxon test (MWW) for
estimating and testing the difference between the two groups
(with associated confidence intervals) [12]. For all statistical
analysis we used “R” (The R Project for Statistical Computing,
www.r-project.org). For figures we utilized “R” package “ggplot2”
[13].
3. Results
Of 125 the patients who met the inclusion criteria, 100
(80%) agreed to participate in the study (Table 1).
3.1. Prevalence of reactions (“total,” N = 100)
We observed 185 HRPA with 376 symptoms in 60 patients
(an average of 3.1 reactions per affected patient). Sixty-five
percent of the reactions led to a change or discontinuation of
antibiotic treatment. In patients with HRPA 46% had ≥ two
and 31% had ≥ three reactions. For pediatric patients (N = 8)
we documented four reactions in three patients. Analysing the
classes of antibiotics, 79% of all reactions occurred after
administration of β-lactam antibiotics. Penicillins accounted
Table 1
Patient characteristics in the different groups.
Group: “Total” “5-Year-doc” “Lifetime-doc” “Pediatric”
N patients 100 66 50 8
Age Ø years 27.9 SD 10.8 28.5 SD 11.6 28.1 SD 13 9 SD 5.1
Sex % male 38 36 39 50
FEV1 Ø % 52.3 SD 25.3 54.4 SD 26.1 55 SD 27.1 71.7 SD 39.2
N courses Ø NA NA 50.4 SD 31.5 21.5 SD 14.4
PA-time in years 16.1 SD 6.6 17.4 SD 6.0 16.7 SD 6.3 5.8 SD 7.7
Atopy screen + % 29 29 32 0
≥1 HRPA in % 60 65 65 38
FEV1 = latest FEV1 in %.
PA-time years = Pseudomas aeruginosa (PA) colonisation time in number of years.
Atopy screen + = screening tests for a common panel of aeroallergens which were positive.
N courses = number of intravenous antibiotic treatment courses.
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quinolones for 4.3% and polypeptides for 4.3% of the reactions.
3.2. Risk of antibiotics to cause hypersensitivity reactions
(“5-year-doc,” N = 66)
In 3205 antibiotic courses analysed, the two antibiotics
with the highest absolute number of HRPA were piperacillin/
tazobactam (N = 63) and ceftazidime (N = 50), both also
accounted for the most anaphylactic HRPA (piperacillin/
tazobactam N = 9, ceftazidime N = 7). The risk among all
evaluated antibiotics was highest for vancomycin (12%). Among
antipseudomonal drugs the risks for HRPA were highest for
cefepime (11%) and piperacillin/tazobactam (10%) (Fig. 1). The8 
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We classified 24% of the HRPA as severe and 15% as
anaphylactic. No HRPA required ICU care.
3.4. Timing of reactions (”total,” N = 100)
In relation to the infusion 53% of HRPA occurred while
administering the antibiotic, 35% within 1 hour and 12% more
than 1 hour after infusion regardless of the day of the treatment
course. In relation to the day of the treatment course 81% of all,
84% of severe and 80% of anaphylactic HRPA occurred between
days 1 and 4 of a treatment course (for combined analysis
see Fig. 2).
3.5. Risk factors for HRPA (“lifetime-doc,” N = 50)
In univariate analyses we identified the following significant
risk factors for an individual to develop HRPA: reduced FEV1,
duration of PA-colonisation and the number of years of iv
antibiotic treatment. In contrast,ΔF508-genotype, sex andmarkers
for atopy such as screening tests for a common panel of
aeroallergens and total IgE concentration were not significant
risk factors. The total number of antibiotic courses and
dichotomous variables like “b20 treatment courses” were not
significantly different between patients with and without
HRPA. While for any type of “reaction” the multivariableFig. 2. Proportion of HRPA related to the day of the treatment course. Divided into im
(group “total,” N = 100) for all HRPA, severe HRPA and anaphylactic HRPA.regression model did not result in significant factors except
for the variable years of PA-colonisation, the results were more
pronounced for “severe reactions” (Table 2). The following
factors were significant predictors of severe HRPA: female sex,
reduced FEV1, and years of PA-colonisation. The addition of the
variable “number of antibiotic courses” did not improve the
estimation in the regression analyses.
3.6. Cumulative dose as a risk factor (“lifetime-doc,” N = 50)
Patients who experienced anHRPA did not differ significantly
in the lifetime dose of the investigated HRPA-causing drugs
from those who did not experience an HRPA. Yet the yearly
cumulative dose of this drug was significantly higher in patients
with reactions than in those without reactions (Table 3).
3.7. Onset of HRPA with respect to initiation of antibiotic
treatment (”lifetime-doc,” N = 50)
Mean age at the beginning of iv treatment was 12.9 (SD 11.6)
years. For patients with at least one HRPA (N = 31) mean age at
the beginning of iv treatment was 12.9 (SD 10.3) years and mean
time from the first exposure to iv antibiotics to the first reaction
was 8.4 (SD 5.6) years. For patients with at least two HRPA
(N = 20) mean age was 13.7 (SD 8.18) years at first iv treatment
and the mean time from first exposure to iv antibiotics to the firstmediate (grey) and non-immediate (black) reactions. Analysed were 185 HRPA
Table 2
Results of the logistic regression analyses identifying potential risk factors for
HRPA and severe HRPA (group “lifetime-doc,” N = 50).
Variable p-Value reactions p-Value severe reactions
Years of PA colonisation 0.0399 0.0324
Reduced FEV1 0.5947 0.0259
Female gender 0.1023 0.0375
Increasing age (continuous) 0.2848 0.3376
Years of antibiotic treatment 0.9130 0.7301
Number of courses 0.4621 0.4801
Atopy screen + 0.6791 0.7501
Atopy screen + = screening tests for a common panel of aeroallergens which
were positive.
Significant results are displayed in bold.
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and second reaction was 2.2 (SD 2.68) years. The time from first
antibiotic treatment to the first reaction was significantly longer
(p b 0.001) than the time from the first to the second reaction.
Having experienced an HRPA to one drug is a risk factor for
developing HRPA against a second drug.
3.8. Therapeutic strategies
Out of the recorded 3205 single drug courses 34 were
done with pre-emptive administration of oral antihistamines
and/or corticosteroids (N = 20) or as a rapid desensitisation [5]
(N = 14) to deal with prior HRPA. Out of those 9/34 (4/20; 5/14)
courses led to another reaction.
4. Discussion
HRPA in CF patients are highly relevant from a clinical
perspective. Patients with advanced CF and an urgent need for
repeated intravenous antibiotic treatment suffer the most from
HRPA, since antibiotic discontinuations and changes of treatment
the anti-infective therapy might be insufficient. HRPA in CF
patients appears to be more frequent than in the general population
[14]. In our study population the prevalence of at least one HRPA
was 60% and therefore higher than in most previous CF studies
analysing antibiotic drug hypersensitivity: 29% in Pleasants et al.
[3], 33% in Wills et al. [1], and 36% in Burrows et al. [2]. Koch
et al. [4] showed a similar prevalence to our study with 61%. TheTable 3
Median cumulative dose per year and life time dose of specific antibiotics as
risk factors.
Exposed
patients a
Patients N Median
lifetime
dose (g)
p Median
cumulative
dose (g)/year
p
Ceftazidime
N = 48
w/ HRPA 18 876 0.92 106 0.012
w/o HRPA 30 860 62
Piperacillin/taz
N = 43
w/ HRPA 22 366 0.063 235 0.011
w/o HRPA 21 702 107
Piperacillin/taz = piperacillin/tazobactam; w/ = with, w/o = without.
Median cumulative dose/year = median cumulative dose until the first HRPA
or until the end of the observation.
a Analysed for the two most frequently HRPA-causing antipseudomonal
antibiotics.inclusion criteria and definitions of HRPA were different among
these reported studies. Even in a direct comparison with Koch's
study [4], our patients experienced nearly twice as many reactions
(3.1 vs. 1.68) per capita. This underlines that HRPA are an
increasing problem in the management of advanced CF.
4.1. Timing of reactions
In our study, 81%of all, 84% of severe and 80%of anaphylactic
reactions occurred during the first 4 days of a treatment course.
These results are of importance for home parenteral antibiotic
treatment. Hospitalisation at start of antibiotic treatment in patients
at risk might be considered to improve safety since reactions
frequently required immediate treatment.
The high magnitude of HRPA on the first day during and
within 1 hour after antibiotic administration suggests a significant
proportion of IgE-mediated reactions. As published before [1–4]
typical IgE mediated skin symptoms such as urticaria and pruritus
were most common.
Several other immunological or other mechanisms may also
cause the spectrum of symptoms we observed with varying times
of onset in the treatment course. A non-immunological mechanism
may be a direct histamine liberation, called pseudoallergy [15],
which has been described for vancomycin (“red-man-syndrome”)
and ciprofloxacin. Another symptom was drug fever with a
proportion of 10% and a trend to occur later in the course, as
previosly published [1–4]. Later in the treatment course we
observed fewer reactions with a larger variety of symptoms in
the sense of cellular delayed hypersensitivity reactions [9,16,17].
Possibly a proportion of the reactions is due to unspecific adverse
effects rather than to specific immunonological mechanisms with
the risk for reoccurrence. Our finding that the time from the first
to the second reaction was significantly decreased has also been
described for penicillin reactions in the general population [18].
4.2. Risk of antibiotics to cause hypersensitivity reactions
As demonstrated, we observed a moderate risk of HRPA
for ceftazidime and higher risks for piperacillin/tazobactam and
cefepime among the antipseudomonal antibiotics. In our study,
the risk of any reaction was almost as high for aztreonam as
that for piperacillin/tazobactam. Aztreonam additionally had the
highest risk for development of severe HRPAwith approximately
6% of all treatment courses leading to a severe reaction. This was
unexpected and is in contrast to previous observations [2,4,19].
Remarkably all patients with HRPA to aztreonam had previously
experienced HRPA to ceftazidime [20].
4.3. Risk factors for HRPA
Our study confirmed in part previous findings [2,21] that
ΔF508 genotype and markers for atopy had no significant
influence on the development of HRPA. Contrary to prior
publications [2,4], neither age nor the total number of antibiotic
treatment courses were significant risk factors. We found the
period of time with PA-colonisation to be a significant predictor
for the development of HRPA. The period of time with PA-
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severe HRPA. Reduced FEV1 and years of PA-colonisation both
might reflect the load of antibiotic treatment per time. Female sex
as a risk factor could be due to the “gender gap” phenomenon
[22,23]. Since in women the disease progresses more rapidly,
they probably have more exposure to antibiotics.
In contrast to a previous publication [2], the total number
of treatment courses and the total lifetime dose of specific
antibiotics had no significant impact on the risk of HRPA.
However, for all evaluated antibiotics, the cumulative dose of a
given antibiotic per time prior to the reaction was significantly
higher among patients with compared to those without reactions.
We focused on the cumulative dose rather than on the number of
treatment courses because antibiotic courses vary broadly in
length and dose. Our observation may be in line with a previously
made suggestion [24] indicating that repeated specific exposure
may increase the risk of HRPA. Our results suggest that
HRPA may occur due to a specific, cumulative-dose dependent
sensitisation. Unfortunately, we have yet to define the underlying
immune reactions leading to different types and time points of
the reaction.
Some strengths and limitations of our study need to be
considered. We were able to record complete data about lifetime
antibiotic exposure and HRPA in 50 patients who had been
treated at our center only, amounting to a follow-up period of up
to 25 years in individual patients. It would not be feasible to
ascertain antibiotic exposure during such a long follow-up period
in a prospective clinical study. Additionally all recalled HRPA
were cross-checked in the medical records. In patients without
lifetime documentation at our center, we had to rely on interview
data in order to ascertain previous (not documented) antibiotic
exposure and HRPA. In these patients, recall bias might be
of concern due to the retrospective nature of our study. We
therefore classified our study population according to the
completeness of the information in the medical records, analysing
lifetime exposure only in the group of patients for whom
full documentation was available. For the analysis of lifetime
antibiotic exposure, this reduced our sample size by half.
Therefore for the analysis of cumulative exposure for specific
antibiotics as a risk factor only ceftazidime and piperacillin/
tazobactam reached evaluable numbers. Just eight pediatric
patients were included due to less iv-antibiotic treatments in
this group nowadays. HRPA is a diffuse clinical phenomenon
with a broad spectrum of symptoms and a range of possible
mechanisms. Facing the difficulty to distinguish between
hypersensitivity reactions and unspecific side effects, we
included all symptoms, which led to patients being labeled as
hypersensitive to an antibiotic. The majority of the reported
symptoms are listed in: “WAO guidelines for anaphylaxis.”
[8]. We took into account that side effects might be included.
This is a limitation since we may have overestimated
HRPA's frequency. Otherwise It may also be a strength to
gather data without fixed definitions. Retrospectively it was
not possible to define HRPA by specific symptoms, since
these may not be fully documented. We therefore defined it
by specific changes to treatment further supporting the
diagnosis of HRPA.In summary, the high frequency of HRPA in our study is
of considerable concern, given the consecutive limitations of
antibiotic treatment options for future therapy of exacerbations
caused by multiresistant gram-negative bacteria [25]. A possible
strategy for prevention of HRPA, which beforehand definitely
requires further confirmation of our findings, could be to rotate
the antipseudomonal agents rather than to repeat the same
regimen which has been well tolerated in past treatments, of
course while keeping the microbiological requirements in mind,
in order to reduce the specific cumulative dose. As clinical
solution several desensitisation protocols have been shown to be
effective [5,7,26], in our observations only 65% were successful.
In order to avoid over-diagnosis of HRPA, diagnostic
algorithms for daily clinical use should be developed. Besides
recent publications [27–30] about drug specific lymphocytes in
CF patients, we believe that further elucidation of HRPA's
immunological mechanisms, also concerning immediate reactions
and diagnostics, is needed. The specific cumulative dose per year
which we observed as a strong predictor for the development of
HRPA requires confirmation in further studies.
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